ATE499934T1 - Verwendung von (3.2.0) heterocyclischen verbindungen und ihren analoga zur behandlung von krebs - Google Patents
Verwendung von (3.2.0) heterocyclischen verbindungen und ihren analoga zur behandlung von krebsInfo
- Publication number
- ATE499934T1 ATE499934T1 AT04776757T AT04776757T ATE499934T1 AT E499934 T1 ATE499934 T1 AT E499934T1 AT 04776757 T AT04776757 T AT 04776757T AT 04776757 T AT04776757 T AT 04776757T AT E499934 T1 ATE499934 T1 AT E499934T1
- Authority
- AT
- Austria
- Prior art keywords
- cancer
- analogues
- treatment
- heterocyclic compounds
- animal
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Biomedical Technology (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Cardiology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US48027003P | 2003-06-20 | 2003-06-20 | |
US56695204P | 2004-04-30 | 2004-04-30 | |
PCT/US2004/019543 WO2005002572A2 (en) | 2003-06-20 | 2004-06-18 | Use of [3.2.0] heterocyclic compounds and analogs thereof for the treatment of cancer, inflammation and infectious diseases |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE499934T1 true ATE499934T1 (de) | 2011-03-15 |
Family
ID=33567612
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT04776757T ATE499934T1 (de) | 2003-06-20 | 2004-06-18 | Verwendung von (3.2.0) heterocyclischen verbindungen und ihren analoga zur behandlung von krebs |
Country Status (14)
Country | Link |
---|---|
US (2) | US20050049294A1 (de) |
EP (1) | EP1638552B1 (de) |
JP (2) | JP2007523862A (de) |
KR (1) | KR20060026052A (de) |
CN (1) | CN102151261A (de) |
AT (1) | ATE499934T1 (de) |
AU (1) | AU2004253478A1 (de) |
BR (1) | BRPI0411677A (de) |
CA (1) | CA2532066C (de) |
DE (1) | DE602004031614D1 (de) |
IL (1) | IL172705A (de) |
MX (1) | MXPA05013982A (de) |
NZ (1) | NZ544588A (de) |
WO (1) | WO2005002572A2 (de) |
Families Citing this family (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1341414B1 (de) * | 2000-11-16 | 2013-01-02 | The Regents of The University of California | Marines actinomyceten-taxon für die wirkstoff-forschung |
US7176232B2 (en) | 2002-06-24 | 2007-02-13 | The Regents Of The University Of California | Salinosporamides and methods for use thereof |
US7179834B2 (en) * | 2002-06-24 | 2007-02-20 | The Regents Of The University Of California | Salinosporamides and methods for use thereof |
PL2441767T3 (pl) * | 2003-06-20 | 2015-11-30 | Univ California | Salinosporamidy i sposoby ich stosowania |
ATE499934T1 (de) | 2003-06-20 | 2011-03-15 | Nereus Pharmaceuticals Inc | Verwendung von (3.2.0) heterocyclischen verbindungen und ihren analoga zur behandlung von krebs |
WO2005051392A1 (en) | 2003-11-20 | 2005-06-09 | Children's Hospital Medical Center | Gtpase inhibitors and methods of use |
WO2005099687A2 (en) * | 2004-04-09 | 2005-10-27 | President And Fellows Of Harvard College | Analogs of salinosporamide a |
US7579371B2 (en) | 2004-04-30 | 2009-08-25 | Nereus Pharmaceuticals, Inc. | Methods of using [3.2.0] heterocyclic compounds and analogs thereof |
MXPA06012421A (es) * | 2004-04-30 | 2007-01-31 | Nereus Pharmaceuticals Inc | Compuestos de heterociclicos y metodos para utilizar los mismos. |
EA200700286A1 (ru) * | 2004-07-12 | 2007-08-31 | Байер Кропсайенс Аг | Применение замещённых производных 2-пирролидона в качестве фунгицидов и инсектицидов |
BRPI0517134A2 (pt) * | 2004-12-03 | 2011-10-11 | Nereus Pharmaceuticals Inc | métodos de uso de compostos heterocìclicos [ 3.2.0 ] e seus análogos |
SG157365A1 (en) * | 2004-12-03 | 2009-12-29 | Dana Farber Cancer Inst Inc | Compositions and methods for treating neoplastic diseases |
US7826982B2 (en) | 2005-07-29 | 2010-11-02 | Children's Hospital Medical Center | Method of identifying inhibitors using a 3-D structure of RAC-1 GTPASE |
EP1931679A4 (de) * | 2005-08-10 | 2009-07-29 | Harvard College | Analoga von salinosporamid a |
US7691896B2 (en) | 2005-08-10 | 2010-04-06 | President And Fellows Of Harvard College | Analogs of salinosporamide A |
US7572606B1 (en) * | 2005-09-09 | 2009-08-11 | Nereus Pharmaceuticals, Inc. | Biosyntheses of salinosporamide A and its analogs and related methods of making salinosporamide A and its analogs |
US7465720B2 (en) * | 2005-09-12 | 2008-12-16 | President And Fellows Of Harvard College | Proteasome inhibiting β-lactam compounds |
CA2628110A1 (en) * | 2005-11-04 | 2007-05-18 | The Regents Of The University Of California | Methods of sensitizing cancer to therapy-induced cytotoxicity |
KR20080109071A (ko) | 2006-04-06 | 2008-12-16 | 니리어스 파마슈티컬즈, 인코퍼레이션 | 살리노스포라마이드 a 및 그의 유도체들의 전합성 |
WO2008097249A2 (en) * | 2006-06-14 | 2008-08-14 | Children's Medical Center Corporation | Method for the treatment of anthrax toxicity |
US8986971B2 (en) | 2006-09-22 | 2015-03-24 | Triphase Research And Development I Corp. | Salt formulations for the fermentation of marine microorganisms |
WO2008095195A2 (en) | 2007-02-02 | 2008-08-07 | Nereus Pharmaceuticals, Inc. | Lyophilized formulations of salinosporamide a |
WO2008137780A2 (en) * | 2007-05-04 | 2008-11-13 | Nereus Pharmaceuticals, Inc. | Use of [3.2.0] heterocyclic compounds and analogs thereof for treating infectious diseases |
US8394816B2 (en) * | 2007-12-07 | 2013-03-12 | Irene Ghobrial | Methods of using [3.2.0] heterocyclic compounds and analogs thereof in treating Waldenstrom's Macroglobulinemia |
EP2088205A1 (de) | 2008-02-11 | 2009-08-12 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | PSMB10: Diagnosemarker und therapeutisches Target für chronische Abstoßung |
AU2009241635A1 (en) | 2008-03-07 | 2009-11-05 | Nereus Pharmaceuticals, Inc. | Total synthesis of Salinosporamide A and analogs thereof |
US20090285836A1 (en) * | 2008-04-14 | 2009-11-19 | Nereus Pharmaceuticals, Inc. | Use of salinosporamide a to inhibit metastasis |
CA2723465A1 (en) | 2008-05-12 | 2009-11-19 | Nereus Pharmaceuticals, Inc. | Proteasome inhibitors |
JP5892791B2 (ja) | 2008-05-14 | 2016-03-23 | ミレニアム ファーマシューティカルズ, インコーポレイテッドMillennium Pharmaceuticals, Inc. | 適応免疫における免疫調節物質の効果をモニターするための方法およびキット |
US8321151B2 (en) | 2008-12-30 | 2012-11-27 | The Invention Science Fund I, Llc | Computational methods and systems for treatment in relation to modulation of CYP450 enzyme activity |
US8073632B2 (en) * | 2008-12-30 | 2011-12-06 | The Invention Science Fund I, Llc | Computational methods and systems for treatment in relation to modulation of CYP450 enzyme activity |
US8315815B2 (en) | 2008-12-30 | 2012-11-20 | The Invention Science Fund I, Llc | Computational methods and systems for suggesting modulators of CYP450 as treatment options |
EP2399129B1 (de) | 2009-02-20 | 2015-11-25 | Michael P. Lisanti | Verfahren zur diagnose bzw. prognose eines neoplasmas einschliesslich der bestimmung des expressionsgrads eines proteins in stromazellen neben dem neoplasma |
US9126997B1 (en) | 2010-09-07 | 2015-09-08 | Northwestern University | Synergistic effect of glucocorticoid receptor agonists in combination with proteosome inhibitors for treating leukemia and myeloma |
US9272014B2 (en) | 2011-03-29 | 2016-03-01 | Texas Tech University System | Galectin-3C combination therapy for human cancer |
JP6238900B2 (ja) | 2011-10-28 | 2017-11-29 | ミレニアム ファーマシューティカルズ, インコーポレイテッドMillennium Pharmaceuticals, Inc. | Nae阻害物質に対する応答のバイオマーカー |
CN104126017A (zh) | 2011-11-11 | 2014-10-29 | 米伦纽姆医药公司 | 对蛋白酶体抑制剂的反应的生物标记 |
EP2810066B1 (de) | 2012-01-24 | 2019-07-31 | Millennium Pharmaceuticals, Inc. | Verfahren zur behandlung von krebs |
US10085987B2 (en) | 2012-01-27 | 2018-10-02 | Thomas Jefferson University | MCT protein inhibitor-related prognostic and therapeutic methods |
US10662477B2 (en) | 2012-10-01 | 2020-05-26 | Millennium Pharmaceuticals, Inc. | Biomarkers and methods to predict response to inhibitors and uses thereof |
CA2890706A1 (en) | 2012-11-09 | 2014-05-15 | Cornell University | Small molecule inhibitors of malt1 |
EP2986290A4 (de) | 2013-04-19 | 2017-01-04 | Thomas Jefferson University | Caveolin-1-verwandte verfahren zur behandlung von glioblastom mit temozolomid |
US10028503B2 (en) | 2014-06-18 | 2018-07-24 | Children's Hospital Medical Center | Platelet storage methods and compositions for same |
US20170348284A1 (en) | 2016-06-01 | 2017-12-07 | Celgene Tri A Holdings Ltd. | Use of marizomib for the treatment of central nervous system (cns) cancers |
JP2019524894A (ja) | 2016-08-19 | 2019-09-05 | セルジーン インターナショナル ツー エスアーエールエル | マリゾミブのモルフィック形態およびその使用 |
KR101953671B1 (ko) * | 2017-08-21 | 2019-03-04 | 충남대학교산학협력단 | 프로테아좀 억제제를 유효성분으로 함유하는 아토피성 피부질환의 예방, 개선 또는 치료용 조성물 |
CN115006532A (zh) * | 2021-03-05 | 2022-09-06 | 广州医科大学 | 蛋白酶体抑制剂的应用 |
Family Cites Families (64)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5133974A (en) * | 1989-05-05 | 1992-07-28 | Kv Pharmaceutical Company | Extended release pharmaceutical formulations |
US5276182A (en) * | 1990-07-09 | 1994-01-04 | The Dow Chemical Company | Process for preparing polyurea oligomers |
DE4039602A1 (de) * | 1990-12-12 | 1992-06-17 | Bauer Kurt Heinz Prof Dr | Pharmazeutische formulierungen |
KR100221695B1 (ko) * | 1991-08-12 | 1999-09-15 | 그린 마틴, 브라이언 쥐 테슬리 | 약학적 구상 제형 |
US5653962A (en) * | 1991-12-12 | 1997-08-05 | Glaxo Group Limited | Aerosol formulations containing P134a and particulate medicaments |
ES2119996T3 (es) * | 1992-11-27 | 1998-10-16 | Napro Biotherapeutics Inc | Composicion inyectable que comprende faclitaxel. |
WO1994017816A1 (en) | 1993-02-10 | 1994-08-18 | The President And Fellows Of Harvard College | Role of atp-ubiquitin-dependent proteolysis in mhc-1 restricted antigen presentation and inhibitors thereof |
US5654286A (en) * | 1993-05-12 | 1997-08-05 | Hostetler; Karl Y. | Nucleotides for topical treatment of psoriasis, and methods for using same |
EP0721335B1 (de) * | 1993-10-01 | 2005-08-31 | Roche Palo Alto LLC | Hochdosierte oral anzuwendende suspensionen enthaltendmycophenolat mofetil |
US5707641A (en) * | 1994-10-13 | 1998-01-13 | Pharmaderm Research & Development Ltd. | Formulations comprising therapeutically-active proteins or polypeptides |
IE80468B1 (en) * | 1995-04-04 | 1998-07-29 | Elan Corp Plc | Controlled release biodegradable nanoparticles containing insulin |
US6838477B2 (en) * | 1995-04-12 | 2005-01-04 | President And Fellows Of Harvard College | Lactacystin analogs |
US6335358B1 (en) * | 1995-04-12 | 2002-01-01 | President And Fellows Of Harvard College | Lactacystin analogs |
US5653987A (en) * | 1995-05-16 | 1997-08-05 | Modi; Pankaj | Liquid formulations for proteinic pharmaceuticals |
US5726181A (en) * | 1995-06-05 | 1998-03-10 | Bionumerik Pharmaceuticals, Inc. | Formulations and compositions of poorly water soluble camptothecin derivatives |
US5667809A (en) * | 1995-06-07 | 1997-09-16 | Alliance Pharmaceutical Corp. | Continuous fluorochemical microdispersions for the delivery of lipophilic pharmaceutical agents |
US5874443A (en) * | 1995-10-19 | 1999-02-23 | Trega Biosciences, Inc. | Isoquinoline derivatives and isoquinoline combinatorial libraries |
US5886210A (en) * | 1996-08-22 | 1999-03-23 | Rohm And Haas Company | Method for preparing aromatic compounds |
ATE240113T1 (de) | 1997-02-15 | 2003-05-15 | Millennium Pharm Inc | Behandlung von infarkten durch inhibierung von nf-kappab |
CA2283636A1 (en) | 1997-03-20 | 1998-09-24 | Variagenics, Inc. | Target genes for allele-specific drugs |
US5922683A (en) * | 1997-05-29 | 1999-07-13 | Abbott Laboratories | Multicyclic erythromycin derivatives |
PT1004573E (pt) | 1997-08-04 | 2003-03-31 | Taisho Pharmaceutical Co Ltd | Derivados de ariloxianilina |
NZ503169A (en) | 1997-08-15 | 2001-12-21 | Millennium Pharm Inc | Synthesis of clasto-lactacystin beta-lactone whereupon the process relies upon a stereoselective addition of a formyl amide to an oxazoline |
US6133308A (en) * | 1997-08-15 | 2000-10-17 | Millennium Pharmaceuticals, Inc. | Synthesis of clasto-lactacystin beta-lactone and analogs thereof |
AU9580098A (en) | 1997-09-25 | 1999-04-12 | Millennium Pharmaceuticals, Inc. | Proteasome inhibitors, ubiquitin pathway inhibitors or agents that interfere with the activation of nf-(k)b via the ubiquitin proteasome pathway to treat inflammatory and autoimmune diseases |
US20010051654A1 (en) * | 1997-09-25 | 2001-12-13 | Elliott Peter J. | Treatment of inflammatory and autoimmune diseases |
CA2219867A1 (en) | 1997-10-31 | 1999-04-30 | Jiangping Wu | The use of proteasome inhibitors for treating cancer, inflammation, autoimmune disease, graft rejection and septic shock |
IL136044A (en) * | 1997-11-21 | 2005-08-31 | Euro Celtique Sa | 2-aminoacetamide derivatives and pharmaceutical compositions containing the same |
US6617171B2 (en) | 1998-02-27 | 2003-09-09 | The General Hospital Corporation | Methods for diagnosing and treating autoimmune disease |
AU752005B2 (en) * | 1998-03-26 | 2002-09-05 | Shionogi & Co., Ltd. | Indole derivatives with antiviral activity |
US6509331B1 (en) * | 1998-06-22 | 2003-01-21 | Elan Pharmaceuticals, Inc. | Deoxyamino acid compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds |
KR20010080267A (ko) * | 1998-10-20 | 2001-08-22 | 밀레니엄 파머슈티컬스 인코퍼레이티드 | 프로테아솜 억제제 약물 작용을 모니터링하는 방법 |
FR2784988B1 (fr) * | 1998-10-23 | 2002-09-20 | Adir | Nouveaux composes dihydro et tetrahydroquinoleiniques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
WO2000033654A1 (en) | 1998-12-04 | 2000-06-15 | University Of Maryland Biotechnology Institute | Use of protease inhibitors to modulate cellular pathways, immunity and therapies associated therewith |
US20020049157A1 (en) | 1999-08-25 | 2002-04-25 | Jiangping Wu | Use of proteasome inhibitors for treating cancer, inflammation, autoimmune disease, graft rejection and septic shock |
CA2425632A1 (en) | 2000-10-12 | 2002-04-18 | Viromics Gmbh | Agents for the treatment of viral infections |
EP1341414B1 (de) * | 2000-11-16 | 2013-01-02 | The Regents of The University of California | Marines actinomyceten-taxon für die wirkstoff-forschung |
US20050203029A1 (en) | 2002-04-05 | 2005-09-15 | Ulrich Schubert | Agents for treating <I>flaviviridae</I>infections |
US7179834B2 (en) * | 2002-06-24 | 2007-02-20 | The Regents Of The University Of California | Salinosporamides and methods for use thereof |
US7176232B2 (en) | 2002-06-24 | 2007-02-13 | The Regents Of The University Of California | Salinosporamides and methods for use thereof |
US20050171022A1 (en) | 2002-07-03 | 2005-08-04 | Charite-Universitaetsmedizin | Proteaseome inhibitors for the treatment of herpesviridae infected individuals |
CA2504933C (en) | 2002-11-06 | 2012-10-16 | Dana-Farber Cancer Institute, Inc. | Methods and compositions for treating cancer using proteasome inhibitors |
WO2004071382A2 (en) * | 2003-02-14 | 2004-08-26 | Bayer Healthcare Ag | Substituted heterocycles |
PL2441767T3 (pl) | 2003-06-20 | 2015-11-30 | Univ California | Salinosporamidy i sposoby ich stosowania |
ATE499934T1 (de) | 2003-06-20 | 2011-03-15 | Nereus Pharmaceuticals Inc | Verwendung von (3.2.0) heterocyclischen verbindungen und ihren analoga zur behandlung von krebs |
US7371875B2 (en) * | 2004-03-12 | 2008-05-13 | Miikana Therapeutics, Inc. | Cytotoxic agents and methods of use |
WO2005099687A2 (en) | 2004-04-09 | 2005-10-27 | President And Fellows Of Harvard College | Analogs of salinosporamide a |
US7183417B2 (en) * | 2004-04-09 | 2007-02-27 | President And Fellows Of Harvard College | Simple stereocontrolled synthesis of salinosporamide A |
US7579371B2 (en) * | 2004-04-30 | 2009-08-25 | Nereus Pharmaceuticals, Inc. | Methods of using [3.2.0] heterocyclic compounds and analogs thereof |
MXPA06012421A (es) * | 2004-04-30 | 2007-01-31 | Nereus Pharmaceuticals Inc | Compuestos de heterociclicos y metodos para utilizar los mismos. |
US20060264495A1 (en) * | 2004-04-30 | 2006-11-23 | Michael Palladino | Methods of using [3.2.0] heterocyclic compounds and analogs thereof |
SG157365A1 (en) | 2004-12-03 | 2009-12-29 | Dana Farber Cancer Inst Inc | Compositions and methods for treating neoplastic diseases |
US20060287520A1 (en) | 2005-05-16 | 2006-12-21 | Danishefsky Samuel J | Synthesis of salinosporamide A and analogues thereof |
US7572606B1 (en) | 2005-09-09 | 2009-08-11 | Nereus Pharmaceuticals, Inc. | Biosyntheses of salinosporamide A and its analogs and related methods of making salinosporamide A and its analogs |
DE102005046344A1 (de) * | 2005-09-28 | 2007-03-29 | Saltigo Gmbh | Verfahren zur Kupplung von Benzylaminen mit Halogenaromaten |
CA2628110A1 (en) * | 2005-11-04 | 2007-05-18 | The Regents Of The University Of California | Methods of sensitizing cancer to therapy-induced cytotoxicity |
GB0605217D0 (en) | 2006-03-15 | 2006-04-26 | Novartis Ag | Method and compositions for assessing acute rejection |
KR20080109071A (ko) | 2006-04-06 | 2008-12-16 | 니리어스 파마슈티컬즈, 인코퍼레이션 | 살리노스포라마이드 a 및 그의 유도체들의 전합성 |
US8088923B2 (en) | 2006-07-07 | 2012-01-03 | The Texas A&M University System | Cyclic-fused beta-lactones and their synthesis |
WO2008137780A2 (en) | 2007-05-04 | 2008-11-13 | Nereus Pharmaceuticals, Inc. | Use of [3.2.0] heterocyclic compounds and analogs thereof for treating infectious diseases |
US8394816B2 (en) | 2007-12-07 | 2013-03-12 | Irene Ghobrial | Methods of using [3.2.0] heterocyclic compounds and analogs thereof in treating Waldenstrom's Macroglobulinemia |
EP2088205A1 (de) | 2008-02-11 | 2009-08-12 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | PSMB10: Diagnosemarker und therapeutisches Target für chronische Abstoßung |
AU2009241635A1 (en) | 2008-03-07 | 2009-11-05 | Nereus Pharmaceuticals, Inc. | Total synthesis of Salinosporamide A and analogs thereof |
CA2723465A1 (en) | 2008-05-12 | 2009-11-19 | Nereus Pharmaceuticals, Inc. | Proteasome inhibitors |
-
2004
- 2004-06-18 AT AT04776757T patent/ATE499934T1/de not_active IP Right Cessation
- 2004-06-18 WO PCT/US2004/019543 patent/WO2005002572A2/en active Application Filing
- 2004-06-18 AU AU2004253478A patent/AU2004253478A1/en not_active Abandoned
- 2004-06-18 CA CA2532066A patent/CA2532066C/en not_active Expired - Lifetime
- 2004-06-18 JP JP2006517404A patent/JP2007523862A/ja not_active Withdrawn
- 2004-06-18 NZ NZ544588A patent/NZ544588A/en unknown
- 2004-06-18 US US10/871,368 patent/US20050049294A1/en not_active Abandoned
- 2004-06-18 KR KR1020057024503A patent/KR20060026052A/ko not_active Application Discontinuation
- 2004-06-18 CN CN2010102534518A patent/CN102151261A/zh active Pending
- 2004-06-18 EP EP04776757A patent/EP1638552B1/de not_active Expired - Lifetime
- 2004-06-18 MX MXPA05013982A patent/MXPA05013982A/es not_active Application Discontinuation
- 2004-06-18 DE DE602004031614T patent/DE602004031614D1/de not_active Expired - Lifetime
- 2004-06-18 BR BRPI0411677-1A patent/BRPI0411677A/pt not_active IP Right Cessation
-
2005
- 2005-12-20 IL IL172705A patent/IL172705A/en active IP Right Grant
-
2008
- 2008-06-10 US US12/136,688 patent/US8168803B2/en active Active
-
2011
- 2011-10-28 JP JP2011238014A patent/JP2012031198A/ja not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
US8168803B2 (en) | 2012-05-01 |
BRPI0411677A (pt) | 2006-08-29 |
DE602004031614D1 (de) | 2011-04-14 |
US20050049294A1 (en) | 2005-03-03 |
WO2005002572A2 (en) | 2005-01-13 |
US20090182027A1 (en) | 2009-07-16 |
KR20060026052A (ko) | 2006-03-22 |
WO2005002572A3 (en) | 2005-05-12 |
IL172705A0 (en) | 2006-04-10 |
JP2007523862A (ja) | 2007-08-23 |
MXPA05013982A (es) | 2006-05-25 |
AU2004253478A1 (en) | 2005-01-13 |
EP1638552A2 (de) | 2006-03-29 |
CA2532066A1 (en) | 2005-01-13 |
EP1638552B1 (de) | 2011-03-02 |
NZ544588A (en) | 2010-06-25 |
IL172705A (en) | 2017-06-29 |
JP2012031198A (ja) | 2012-02-16 |
CA2532066C (en) | 2015-07-28 |
CN102151261A (zh) | 2011-08-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE499934T1 (de) | Verwendung von (3.2.0) heterocyclischen verbindungen und ihren analoga zur behandlung von krebs | |
WO2006060809A3 (en) | Methods of using [3.2.0] heterocyclic compounds and analogs thereof | |
CY1118651T1 (el) | Αζακυκλικες ενωσεις για χρηση στην θεραπευτικη αντιμετωπιση ασθενειων που σχετιζονται με τη σεροτονινη | |
ATE355374T1 (de) | Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen | |
DE60124085D1 (de) | Pde-v hemmer zur behandlung von morbus parkinson | |
NO20074999L (no) | Metode og preparat for behandling av perifere vaskulaere sykdommer | |
DE60227658D1 (de) | Verfahren zur behandlung neurodegenerativer, psychiatrischer und anderer störungen mit deacetylaseinhibitoren | |
ATE412646T1 (de) | Zur behandlung von schmerzen geeignete therapeutische mittel | |
DE60303238D1 (de) | Pyrimidin-Essigsäure Derivate geeignet zur Behandlung von CRTH2-bedingten Krankheiten | |
ATE456955T1 (de) | Verwendung von cyclodextrin zur behandlung und vorbeugung von entzündlichen bronchialerkrankungen | |
ATE446102T1 (de) | Behandlung von gewichtsverlust bei patienten mit entzündlichen darmerkrankungen mittels s. boulardii | |
ATE396174T1 (de) | Hydroxyalkylaminderivate als beta-secretase- inhibitoren und deren verwendung zur behandlung der alzheimerschen krankheit oder ähnlicher krankheiten | |
CY1107985T1 (el) | Ccr1 ανταγωνιστες για την αγωγη μεταξυ αλλων απομυελινωτικης φλεγμονωδους νοσου | |
EA200501820A1 (ru) | Терапевтические средства для лечения боли | |
EA200700407A1 (ru) | Производные хиназолина и их использования при лечении тромбоцитемии | |
ATE520691T1 (de) | Shp-2-hemmer, pharmazeutische zusammensetzung damit und ihre verwendung zur behandlung phosphatase-vermittelter erkrankungen | |
ATE424824T1 (de) | Verfahren zur verhütung oder behandlung von herzarrhythmie | |
CY1119257T1 (el) | Θεραπεια του νευροπαθητικου πονου με ανταγωνιστες υποδοχεα δεξτρομεθορφανης n-meθυλ-d-ασπαρτικων (nmda) | |
ATE281841T1 (de) | Verfahren zur herstellung von mikania extrakten enthaltend mikanolide und dihydromikanolide und verwendung in der behandlung proliferativer erkrankungen | |
DE60005952D1 (de) | Löslische hla-g enthaltende zusammensetsungen zur behandlung entzündlichen hautkrankheiten | |
ATE262330T1 (de) | Verwendung eines nitroxids oder seiner prodrugs zur prophylaktischen und therapeutischen behandlung von krebs | |
DE60224429D1 (de) | Pharmazeutische zusammensetzung zur verwendung bei der behandlung von malignen erkrankungen, umfassend eine kombination aus bisphosphonaten, einem cox-2 inhibitor und einem taxol | |
DK1596879T3 (da) | Anvendelse af kahalalidforbindelser til fremstilling af et medikament til behandling af psoriasis | |
ATE359995T1 (de) | Amin-1,2- und -1,3-diolverbindungen und deren verwendung zur behandlung von alzheimer-krankheit | |
ATE359270T1 (de) | Phenyl-piperidin-4-yliden-methyl-benzamidderiva e zur behandlung von schmerz oder magen-darm- erkrankungen |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |